Finally, in 2022, Kivisäkk and colleagues detected significantly increased levels of SNAP-25 in AD patients compared to other NDs, suggesting its role as a potential AD-specific biomarker [81]. This evidence concerns the gene SNAP25 and Alzheimer disease.